{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:17:39Z","timestamp":1793089059942,"version":"4.5.0"},"reference-count":157,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prolactinoma is a significant cause of hyperprolactinemia and the most common type of pituitary tumor. Women of fertile age are most commonly affected, and the clinical picture is characterized by galactorrhea, oligo-amenorrhea, and infertility. In microprolactinomas, which represent more than 60% of cases in women before menopause, there is usually no concern about the mass effect. Therefore, management can be expectant if there are no symptoms or in a patient in the postmenopausal period; oral contraceptive in the presence of hypogonadism and no desire for pregnancy; dopamine agonist (DA) in the presence of bothersome galactorrhea, hypogonadism, and the desire for fertility; and neurosurgery in selected noninvasive cases. Resistance to DA occurs in less than 10% of cases. Although the reduction in dopamine receptor subtype 2 expression is considered the primary cause of DA resistance, the underlying mechanisms are not yet completely elucidated. The main concern in resistant cases is the risk of symptomatic tumor growth during assisted reproduction techniques and pregnancy. Other conditions in which hyperprolactinemia could be implicated, such as metabolic parameters, osteoporosis, and breast cancer risk are also discussed. Understanding the mechanisms of DA resistance can lead to the opening of new treatment strategies.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf624","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T13:02:54Z","timestamp":1763038974000},"page":"879-891","source":"Crossref","is-referenced-by-count":3,"title":["Approach to the Patient With Dopamine-Resistant Microprolactinoma"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8201-6756","authenticated-orcid":false,"given":"Andrea","family":"Glezer","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School , Sao Paulo 05403-010 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-0972","authenticated-orcid":false,"given":"Matheo Augusto Morandi","family":"Stumpf","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School , Sao Paulo 05403-010 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1597-6616","authenticated-orcid":false,"given":"Nara Lima","family":"Queiroz","sequence":"additional","affiliation":[{"name":"Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clinicas, University of Sao Paulo Medical School , Sao Paulo 05403-010 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"3","key":"2026021918520177800_dgaf624-B1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"2026021918520177800_dgaf624-B2","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2026021918520177800_dgaf624-B3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026021918520177800_dgaf624-B4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026021918520177800_dgaf624-B5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: any alternative medical treatment?","volume":"23","author":"Souteiro","year":"2020","journal-title":"Pituitary"},{"issue":"2","key":"2026021918520177800_dgaf624-B6","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026021918520177800_dgaf624-B7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: any differences?","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"key":"2026021918520177800_dgaf624-B8","doi-asserted-by":"crossref","first-page":"1338345","DOI":"10.3389\/fendo.2024.1338345","article-title":"Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment","volume":"15","author":"Dzialach","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026021918520177800_dgaf624-B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ecl.2014.11.003","article-title":"Prolactinomas","volume":"44","author":"Glezer","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"2026021918520177800_dgaf624-B10","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"2026021918520177800_dgaf624-B11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021918520177800_dgaf624-B12","first-page":"63","article-title":"Macroprolactin: from laboratory to clinical practice","volume":"69","author":"Biagetti","year":"2022","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"2026021918520177800_dgaf624-B13","volume-title":"Endotext","author":"Monteiro","year":"2025"},{"issue":"8","key":"2026021918520177800_dgaf624-B14","doi-asserted-by":"crossref","first-page":"102883","DOI":"10.1016\/j.arcmed.2023.102883","article-title":"Prolactinomas resistant to dopamine agonists: pathophysiology and treatment","volume":"54","author":"Shimon","year":"2023","journal-title":"Arch Med Res"},{"issue":"10","key":"2026021918520177800_dgaf624-B15","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1210\/jc.2016-2008","article-title":"Dopamine agonists can reduce cystic prolactinomas","volume":"101","author":"Faje","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021918520177800_dgaf624-B16","doi-asserted-by":"crossref","first-page":"e230504","DOI":"10.20945\/2359-4292-2023-0504","article-title":"Treatment of hyperprolactinemia in women: a position statement from the Brazilian federation of gynecology and obstetrics associations (Febrasgo) and the Brazilian society of endocrinology and metabolism (SBEM)","volume":"68","author":"Benetti-Pinto","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"7","key":"2026021918520177800_dgaf624-B17","doi-asserted-by":"crossref","first-page":"e250054","DOI":"10.1530\/EC-25-0054","article-title":"Hyperprolactinemia caused by extra-pituitary prolactin secretion: a systematic review","volume":"14","author":"Lu","year":"2025","journal-title":"Endocr Connect"},{"issue":"7","key":"2026021918520177800_dgaf624-B18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/014107689909200704","article-title":"Three cases of macroprolactinaemia","volume":"92","author":"Olukoga","year":"1999","journal-title":"J R Soc Med"},{"issue":"2","key":"2026021918520177800_dgaf624-B19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3171\/jns.2001.95.2.0334","article-title":"Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. Case report","volume":"95","author":"Cattaneo","year":"2001","journal-title":"J Neurosurg"},{"issue":"5","key":"2026021918520177800_dgaf624-B20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1530\/eje.0.1300438","article-title":"Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody","volume":"130","author":"Hattori","year":"1994","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026021918520177800_dgaf624-B21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2362.2007.01823.x","article-title":"Patients with macroprolactinaemia: clinical and radiological features","volume":"37","author":"Donadio","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"2026021918520177800_dgaf624-B22","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1373\/49.9.1504","article-title":"Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia","volume":"49","author":"Suliman","year":"2003","journal-title":"Clin Chem"},{"issue":"1","key":"2026021918520177800_dgaf624-B23","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41598-021-89256-7","article-title":"Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis","volume":"11","author":"Leca","year":"2021","journal-title":"Sci Rep"},{"key":"2026021918520177800_dgaf624-B24","doi-asserted-by":"crossref","first-page":"e230391","DOI":"10.20945\/2359-4292-2023-0391","article-title":"Usefulness of prolactin levels in predicting the etiology of hyperprolactinemia in a cohort of 770 patients","volume":"68","author":"Vilar","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2026021918520177800_dgaf624-B25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/09513590.2017.1379501","article-title":"Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report","volume":"34","author":"Sato","year":"2018","journal-title":"Gynecol Endocrinol"},{"issue":"11","key":"2026021918520177800_dgaf624-B26","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1210\/jc.2014-2623","article-title":"Ectopic prolactin secretion from a perivascular epithelioid cell tumor (PEComa)","volume":"99","author":"Korytnaya","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918520177800_dgaf624-B27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026021918520177800_dgaf624-B28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11102-005-5086-1","article-title":"Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists","volume":"8","author":"Hamilton","year":"2005","journal-title":"Pituitary"},{"issue":"2","key":"2026021918520177800_dgaf624-B29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12020-022-03080-1","article-title":"Resistant prolactinomas: a case series of 26 patients","volume":"77","author":"Eshkoli","year":"2022","journal-title":"Endocrine"},{"issue":"3","key":"2026021918520177800_dgaf624-B30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","article-title":"The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European multicentre cabergoline study group","volume":"39","author":"Webster","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"14","key":"2026021918520177800_dgaf624-B31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"9","key":"2026021918520177800_dgaf624-B32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients","volume":"20","author":"Muratori","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2026021918520177800_dgaf624-B33","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918520177800_dgaf624-B34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma","volume":"22","author":"Cannav\u00f2","year":"1999","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2026021918520177800_dgaf624-B35","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026021918520177800_dgaf624-B36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2026021918520177800_dgaf624-B37","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026021918520177800_dgaf624-B38","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026021918520177800_dgaf624-B39","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026021918520177800_dgaf624-B40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"2026021918520177800_dgaf624-B41","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3390\/jcm11113070","article-title":"Dopamine agonist-resistant microprolactinoma-mechanisms, predictors and management: a case report and literature review","volume":"11","author":"Szmygin","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"2026021918520177800_dgaf624-B42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12020-025-04215-w","article-title":"Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study","volume":"89","author":"Rudman","year":"2025","journal-title":"Endocrine"},{"key":"2026021918520177800_dgaf624-B43","doi-asserted-by":"crossref","first-page":"791633","DOI":"10.3389\/fendo.2021.791633","article-title":"Resistance to dopamine agonists in pituitary tumors: molecular mechanisms","volume":"12","author":"Pivonello","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026021918520177800_dgaf624-B44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2026021918520177800_dgaf624-B45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000156116","article-title":"Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists","volume":"89","author":"Passos","year":"2009","journal-title":"Neuroendocrinology"},{"issue":"10","key":"2026021918520177800_dgaf624-B46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2826.1996.04902.x","article-title":"Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas","volume":"8","author":"Caccavelli","year":"1996","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2026021918520177800_dgaf624-B47","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2011-2902","article-title":"Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs","volume":"97","author":"Peverelli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918520177800_dgaf624-B48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/tpj.2008.1","article-title":"Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas","volume":"8","author":"Filopanti","year":"2008","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"2026021918520177800_dgaf624-B49","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/hmg\/ddy396","article-title":"Association of prolactin receptor (PRLR) variants with prolactinomas","volume":"28","author":"Gorvin","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"7","key":"2026021918520177800_dgaf624-B50","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1210\/clinem\/dgad020","article-title":"PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance","volume":"108","author":"de Castro Moreira","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021918520177800_dgaf624-B51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mce.2014.12.024","article-title":"The role of TGF-\u03b2\/Smad signaling in dopamine agonist-resistant prolactinomas","volume":"402","author":"Li","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2026021918520177800_dgaf624-B52","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1530\/JOE-15-0451","article-title":"The pituitary TGF\u03b21 system as a novel target for the treatment of resistant prolactinomas","volume":"228","author":"Recouvreux","year":"2016","journal-title":"J Endocrinol"},{"key":"2026021918520177800_dgaf624-B53","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainres.2018.07.024","article-title":"Role of TGF-\u03b21\/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma","volume":"1698","author":"Hu","year":"2018","journal-title":"Brain Res"},{"issue":"3","key":"2026021918520177800_dgaf624-B54","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11060-025-04949-7","article-title":"Cabergoline-induced NDFIP1 upregulation in pituitary neuroendocrine tumor cells activates mTOR signaling and contributes to cabergoline resistance","volume":"172","author":"Gu","year":"2025","journal-title":"J Neurooncol"},{"issue":"5","key":"2026021918520177800_dgaf624-B55","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000517356","article-title":"MicroRNAs in dopamine agonist-resistant prolactinoma","volume":"112","author":"Wan","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026021918520177800_dgaf624-B56","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"2026021918520177800_dgaf624-B57","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","article-title":"Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours","volume":"189","author":"Simon","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2026021918520177800_dgaf624-B58","doi-asserted-by":"crossref","first-page":"e1022","DOI":"10.1002\/mgg3.1022","article-title":"Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma","volume":"7","author":"Miao","year":"2019","journal-title":"Mol Genet Genomic Med"},{"key":"2026021918520177800_dgaf624-B59","doi-asserted-by":"crossref","first-page":"1195792","DOI":"10.3389\/fendo.2023.1195792","article-title":"Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas","volume":"14","author":"Medina","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026021918520177800_dgaf624-B60","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1210\/clinem\/dgae615","article-title":"Somatic activating ESR1 mutation in an aggressive prolactinoma","volume":"110","author":"Paes","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026021918520177800_dgaf624-B61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1530\/EJE-14-0990","article-title":"Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth","volume":"172","author":"Delgrange","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026021918520177800_dgaf624-B62","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2213-8587(25)00118-4","article-title":"Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis","volume":"13","author":"English","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2026021918520177800_dgaf624-B63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s12020-018-1765-3","article-title":"T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists","volume":"63","author":"Burlacu","year":"2019","journal-title":"Endocrine"},{"issue":"7","key":"2026021918520177800_dgaf624-B64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","article-title":"Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference","volume":"57","author":"Kreutz","year":"2015","journal-title":"Neuroradiology"},{"issue":"1","key":"2026021918520177800_dgaf624-B65","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000499382","article-title":"Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours","volume":"109","author":"Trouillas","year":"2019","journal-title":"Neuroendocrinology"},{"key":"2026021918520177800_dgaf624-B66","doi-asserted-by":"crossref","first-page":"616339","DOI":"10.3389\/fendo.2021.616339","article-title":"Case report: temozolomide treatment of refractory prolactinoma resistant to dopamine agonists","volume":"12","author":"Tang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026021918520177800_dgaf624-B67","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026021918520177800_dgaf624-B68","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1227\/00006123-198302000-00008","article-title":"Natural history of microprolactinomas: six-year follow-up","volume":"12","author":"Weiss","year":"1983","journal-title":"Neurosurgery"},{"issue":"1","key":"2026021918520177800_dgaf624-B69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","article-title":"The natural history of untreated microprolactinomas","volume":"48","author":"Sisam","year":"1987","journal-title":"Fertil Steril"},{"issue":"2","key":"2026021918520177800_dgaf624-B70","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1210\/jcem-68-2-412","article-title":"The natural history of untreated hyperprolactinemia: a prospective analysis","volume":"68","author":"Schlechte","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918520177800_dgaf624-B71","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s11102-024-01452-6","article-title":"Natural history of untreated microprolactinomas","volume":"27","author":"Sadek","year":"2024","journal-title":"Pituitary"},{"issue":"1","key":"2026021918520177800_dgaf624-B72","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10143-024-02951-7","article-title":"A multicenter study of clinical outcomes and volumetric trends in suspected microprolactinomas","volume":"47","author":"Hong","year":"2024","journal-title":"Neurosurg Rev"},{"issue":"1","key":"2026021918520177800_dgaf624-B73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1590\/2359-3997000000138","article-title":"Prolactinomas: evolution after menopause","volume":"60","author":"Mallea-Gil","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"2026021918520177800_dgaf624-B74","doi-asserted-by":"crossref","first-page":"e3701","DOI":"10.1210\/clinem\/dgaf152","article-title":"Menopause has a beneficial influence on the evolution of prolactinomas. A study of 99 patients","volume":"110","author":"Constantinescu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026021918520177800_dgaf624-B75","first-page":"745","article-title":"Osteoporotic fractures in patients with untreated hyperprolactinemia vs. Those taking dopamine agonists: a systematic review and meta-analysis","volume":"36","author":"D'Sylva","year":"2015","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"2026021918520177800_dgaf624-B76","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1038\/s41598-021-84606-x","article-title":"Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas","volume":"11","author":"Andereggen","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"2026021918520177800_dgaf624-B77","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s11102-024-01469-x","article-title":"Modern approach to bone comorbidity in prolactinoma","volume":"27","author":"Uygur","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2026021918520177800_dgaf624-B78","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3390\/ijms25031474","article-title":"Effect of hyperprolactinemia on bone metabolism: focusing on osteopenia\/osteoporosis","volume":"25","author":"Yun","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2026021918520177800_dgaf624-B79","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMcibr2409260","article-title":"Building bone while making milk","volume":"391","author":"Hofbauer","year":"2024","journal-title":"N Engl J Med"},{"issue":"8024","key":"2026021918520177800_dgaf624-B80","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41586-024-07634-3","article-title":"A maternal brain hormone that builds bone","volume":"632","author":"Babey","year":"2024","journal-title":"Nature"},{"issue":"5","key":"2026021918520177800_dgaf624-B81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026021918520177800_dgaf624-B82","doi-asserted-by":"crossref","first-page":"1015520","DOI":"10.3389\/fendo.2022.1015520","article-title":"Metabolic effects of prolactin","volume":"13","author":"Pirchio","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026021918520177800_dgaf624-B83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000486000","article-title":"Metabolic syndrome in hyperprolactinemia","volume":"49","author":"Andersen","year":"2018","journal-title":"Front Horm Res"},{"key":"2026021918520177800_dgaf624-B84","doi-asserted-by":"crossref","first-page":"1018090","DOI":"10.3389\/fendo.2022.1018090","article-title":"The interplay between prolactin and cardiovascular disease","volume":"13","author":"Glezer","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026021918520177800_dgaf624-B85","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000494725","article-title":"Hyperprolactinemia\/prolactinomas in the postmenopausal period: challenges in diagnosis and management","volume":"109","author":"Peki\u0107","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"10","key":"2026021918520177800_dgaf624-B86","doi-asserted-by":"crossref","first-page":"bqac122","DOI":"10.1210\/endocr\/bqac122","article-title":"Breast cancer and prolactin\u2014new mechanisms and models","volume":"163","author":"Clevenger","year":"2022","journal-title":"Endocrinology"},{"issue":"1","key":"2026021918520177800_dgaf624-B87","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0531-5565(99)00078-9","article-title":"Involvement of prolactin in breast cancer: redefining the molecular targets","volume":"35","author":"Llovera","year":"2000","journal-title":"Exp Gerontol"},{"issue":"15","key":"2026021918520177800_dgaf624-B88","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"2026021918520177800_dgaf624-B89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11102-009-0214-y","article-title":"The risk for breast cancer is not evidently increased in women with hyperprolactinemia","volume":"13","author":"Dekkers","year":"2010","journal-title":"Pituitary"},{"issue":"3","key":"2026021918520177800_dgaf624-B90","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-024-02492-2","article-title":"Breast cancer risk in patients with dopamine agonist-treated hyperprolactinemia","volume":"48","author":"Dery","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026021918520177800_dgaf624-B91","doi-asserted-by":"crossref","first-page":"e250108","DOI":"10.1530\/EC-25-0108","article-title":"Hyperprolactinemia and cancer risk: a Swedish population-based cohort study","volume":"14","author":"Himonakos","year":"2025","journal-title":"Endocr Connect"},{"issue":"2","key":"2026021918520177800_dgaf624-B92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13691-024-00741-y","article-title":"Resistant PRL-secreting PitNET associated with breast carcinoma: a case report and literature review","volume":"14","author":"Dumitriu-Stan","year":"2025","journal-title":"Int Cancer Conf J"},{"issue":"1","key":"2026021918520177800_dgaf624-B93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12672-018-0348-3","article-title":"Familial cancer clustering in patients with prolactinoma","volume":"10","author":"Pekic","year":"2019","journal-title":"Horm Cancer"},{"issue":"1","key":"2026021918520177800_dgaf624-B94","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13256-018-1890-x","article-title":"Giant prolactinoma, germline BRCA1 mutation, and depression: a case report","volume":"12","author":"Bettencourt-Silva","year":"2018","journal-title":"J Med Case Rep"},{"issue":"1","key":"2026021918520177800_dgaf624-B95","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11102-019-00998-0","article-title":"Prolactinomas and menopause: any changes in management?","volume":"23","author":"Greenman","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2026021918520177800_dgaf624-B96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11102-020-01039-x","article-title":"Do nothing but observe microprolactinomas: when and how to replace sex hormones?","volume":"23","author":"Bonert","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2026021918520177800_dgaf624-B97","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/09513599209015553","article-title":"The effect of combined estrogen\/progestogen treatment in women with hyperprolactinemic amenorrhea","volume":"6","author":"Fahy","year":"1992","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"2026021918520177800_dgaf624-B98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"issue":"3","key":"2026021918520177800_dgaf624-B99","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertil Steril"},{"issue":"5","key":"2026021918520177800_dgaf624-B100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0020-7292(81)90021-7","article-title":"Oral contraceptive exposure of amenorrheic women with and without prolactinomas","volume":"19","author":"Jones","year":"1981","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"2026021918520177800_dgaf624-B101","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9378(82)90641-X","article-title":"Oral contraceptives and prolactinomas: a case-control study","volume":"143","author":"Maheux","year":"1982","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2026021918520177800_dgaf624-B102","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/BF03349744","article-title":"Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy","volume":"18","author":"Garcia","year":"1995","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2026021918520177800_dgaf624-B103","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1471-0528.1989.tb06310.x","article-title":"Development of an invasive macroprolactinoma: a possible consequence of prolonged oestrogen replacement. Case report","volume":"96","author":"Bevan","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"issue":"1","key":"2026021918520177800_dgaf624-B104","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026021918520177800_dgaf624-B105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12020-024-03817-0","article-title":"Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism","volume":"85","author":"Stumpf","year":"2024","journal-title":"Endocrine"},{"issue":"6","key":"2026021918520177800_dgaf624-B106","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1590\/2359-3997000000230","article-title":"Interactions between prolactin and kisspeptin to control reproduction","volume":"60","author":"Donato","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"10","key":"2026021918520177800_dgaf624-B107","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1172\/JCI63937","article-title":"Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration","volume":"122","author":"Sonigo","year":"2012","journal-title":"J Clin Invest"},{"issue":"8","key":"2026021918520177800_dgaf624-B108","doi-asserted-by":"crossref","first-page":"e3515","DOI":"10.1210\/clinem\/dgac166","article-title":"Kisspeptin overcomes GnRH neuronal suppression secondary to hyperprolactinemia in humans","volume":"107","author":"Hoskova","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026021918520177800_dgaf624-B109","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.fertnstert.2009.12.017","article-title":"Prevalence of hyperprolactinemia and abnormal magnetic resonance imaging findings in a population with infertility","volume":"94","author":"Souter","year":"2010","journal-title":"Fertil Steril"},{"issue":"5","key":"2026021918520177800_dgaf624-B110","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1472-6483(10)61166-2","article-title":"Hyperprolactinaemia and the regular menstrual cycle in asymptomatic women: should it be treated during therapy for infertility?","volume":"11","author":"Nawroth","year":"2005","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"2026021918520177800_dgaf624-B111","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ando.2022.04.002","article-title":"Mild hyperprolactinemia in a couple: what impact on fertility?","volume":"83","author":"Maiter","year":"2022","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"2026021918520177800_dgaf624-B112","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11102-023-01313-8","article-title":"How to manage intolerance to dopamine agonist in patients with prolactinoma","volume":"26","author":"Stumpf","year":"2023","journal-title":"Pituitary"},{"issue":"3","key":"2026021918520177800_dgaf624-B113","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.4158\/EP10369.CR","article-title":"Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas","volume":"17","author":"Iyer","year":"2011","journal-title":"Endocr Pract"},{"issue":"6","key":"2026021918520177800_dgaf624-B114","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1210\/jc.2009-2605","article-title":"Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas","volume":"95","author":"Ono","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026021918520177800_dgaf624-B115","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"Molitch","year":"2014","journal-title":"J Neurooncol"},{"issue":"10","key":"2026021918520177800_dgaf624-B116","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma","volume":"87","author":"Gillam","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918520177800_dgaf624-B117","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026021918520177800_dgaf624-B118","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"2026021918520177800_dgaf624-B119","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cen.13940","article-title":"Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British society of echocardiography, the British heart valve society and the society for endocrinology","volume":"90","author":"Steeds","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2026021918520177800_dgaf624-B120","doi-asserted-by":"crossref","first-page":"102910","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch Med Res"},{"issue":"1","key":"2026021918520177800_dgaf624-B121","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026021918520177800_dgaf624-B122","doi-asserted-by":"crossref","first-page":"111363","DOI":"10.1016\/j.jocn.2025.111363","article-title":"Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis","volume":"138","author":"Penchev","year":"2025","journal-title":"J Clin Neurosci"},{"key":"2026021918520177800_dgaf624-B123","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fendo.2018.00636","article-title":"The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026021918520177800_dgaf624-B124","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1210\/clinem\/dgz144","article-title":"Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis","volume":"105","author":"Zamanipoor Najafabadi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026021918520177800_dgaf624-B125","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2265.1987.tb00809.x","article-title":"Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy","volume":"26","author":"Bevan","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026021918520177800_dgaf624-B126","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00701-024-06198-5","article-title":"Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients","volume":"166","author":"Ryba","year":"2024","journal-title":"Acta Neurochir (Wien)"},{"key":"2026021918520177800_dgaf624-B127","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clineuro.2018.11.024","article-title":"Fertility after transsphenoidal surgery in patients with prolactinomas: a meta-analysis","volume":"176","author":"Lamba","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"2026021918520177800_dgaf624-B128","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12020-018-1652-y","article-title":"Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery","volume":"62","author":"Yi","year":"2018","journal-title":"Endocrine"},{"issue":"12 Suppl","key":"2026021918520177800_dgaf624-B129","first-page":"1116","article-title":"Management of hyperprolactinemia in infertility","volume":"44","author":"Crosignani","year":"1999","journal-title":"J Reprod Med"},{"issue":"2","key":"2026021918520177800_dgaf624-B130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0015-0282(16)44178-6","article-title":"Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin of bromocriptine","volume":"32","author":"Radwanska","year":"1979","journal-title":"Fertil Steril"},{"issue":"6","key":"2026021918520177800_dgaf624-B131","first-page":"708","article-title":"Spontaneous and induced pregnancies in hyperprolactinemic women","volume":"58","author":"Crosignani","year":"1981","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2026021918520177800_dgaf624-B132","doi-asserted-by":"crossref","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"The Eshre Guideline Group On Ovarian Stimulation","year":"2020","journal-title":"Hum Reprod Open"},{"issue":"2","key":"2026021918520177800_dgaf624-B133","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.fertnstert.2009.02.066","article-title":"Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of in vitro fertilization in a concentration-dependent manner","volume":"93","author":"Joo","year":"2010","journal-title":"Fertil Steril"},{"issue":"3","key":"2026021918520177800_dgaf624-B134","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.fertnstert.2005.02.045","article-title":"Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry","volume":"84","author":"Soldin","year":"2005","journal-title":"Fertil Steril"},{"issue":"3","key":"2026021918520177800_dgaf624-B135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"2026021918520177800_dgaf624-B136","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026021918520177800_dgaf624-B137","doi-asserted-by":"crossref","first-page":"2490132","DOI":"10.1155\/crie\/2490132","article-title":"Microprolactinoma growth during pregnancy with pituitary tumor apoplexy: case report and review of the literature","volume":"2025","author":"Introini","year":"2025","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"2026021918520177800_dgaf624-B138","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-21-0145","article-title":"Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature","volume":"185","author":"Kuhn","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026021918520177800_dgaf624-B139","doi-asserted-by":"crossref","first-page":"423","DOI":"10.23736\/S0391-1977.17.02792-4","article-title":"Prolactinomas: how to handle prior to and during pregnancy?","volume":"43","author":"Glezer","year":"2018","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"2026021918520177800_dgaf624-B140","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026021918520177800_dgaf624-B141","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11102-019-01010-5","article-title":"Prolactinomas in pregnancy: considerations before conception and during pregnancy","volume":"23","author":"Glezer","year":"2020","journal-title":"Pituitary"},{"issue":"10","key":"2026021918520177800_dgaf624-B142","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.3390\/jcm12103416","article-title":"Challenges of pituitary apoplexy in pregnancy","volume":"12","author":"Gheorghe","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"2026021918520177800_dgaf624-B143","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1210\/clinem\/dgae821","article-title":"Disease activity and maternal-fetal outcomes in pregnant women with prolactinoma: a systematic review and meta-analysis","volume":"110","author":"Bandeira","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026021918520177800_dgaf624-B144","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026021918520177800_dgaf624-B145","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s11102-021-01165-0","article-title":"Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients","volume":"24","author":"Ceccato","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"2026021918520177800_dgaf624-B146","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/jcm12041437","article-title":"The role of aromatase inhibitors in male prolactinoma","volume":"12","author":"Akirov","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"2026021918520177800_dgaf624-B147","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40618-023-02231-z","article-title":"Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review","volume":"47","author":"Z\u00fa\u00f1iga","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026021918520177800_dgaf624-B148","first-page":"491","article-title":"Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen","volume":"101","author":"V\u00f6lker","year":"1982","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"4","key":"2026021918520177800_dgaf624-B149","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1530\/eje.0.1470461","article-title":"Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women","volume":"147","author":"Lasco","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026021918520177800_dgaf624-B150","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-19-0359","article-title":"Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors","volume":"181","author":"Raverot","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026021918520177800_dgaf624-B151","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12020-018-1638-9","article-title":"Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR","volume":"61","author":"Sosa-Eroza","year":"2018","journal-title":"Endocrine"},{"key":"2026021918520177800_dgaf624-B152","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.wneu.2018.02.188","article-title":"Combination treatment with bromocriptine and metformin in patients with bromocriptine-resistant prolactinomas: pilot study","volume":"115","author":"Liu","year":"2018","journal-title":"World Neurosurg"},{"issue":"8","key":"2026021918520177800_dgaf624-B153","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1210\/jc.2019-00056","article-title":"Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms","volume":"104","author":"V\u00e1zquez-Borrego","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026021918520177800_dgaf624-B154","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000514591","article-title":"Prolactin response to metformin in cabergoline-resistant prolactinomas: a pilot study","volume":"112","author":"Portari","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2026021918520177800_dgaf624-B155","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026021918520177800_dgaf624-B156","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40478-025-02025-9","article-title":"Spatial transcriptomics reveal PI3K-AKT and metabolic alterations in aggressive, treatment-resistant lactotroph pituitary neuroendocrine tumors","volume":"13","author":"Martinez-Mendoza","year":"2025","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"2026021918520177800_dgaf624-B157","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000515801","article-title":"MicroRNA-mediated drug repurposing unveiled potential candidate drugs for prolactinoma treatment","volume":"112","author":"Aydin","year":"2022","journal-title":"Neuroendocrinology"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf624\/65288039\/dgaf624.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/879\/65288039\/dgaf624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/3\/879\/65288039\/dgaf624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:52:34Z","timestamp":1771545154000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/3\/879\/8322885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":157,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,14]]},"published-print":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf624","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,14]]}}}